Bronchiectasis

The Healio Editors have compiled a list of the most-read news in pulmonology posted in August.

Older adults with nontuberculous mycobacterial pulmonary disease have significantly greater likelihood for hospitalization, higher hospitalization rates and shorter time to hospitalization than those without, researchers reported.

This week, the CDC confirms a fatal case of melioidosis in Georgia; Moderna says its vaccine is 93% effective at 6 months; a survey shows patients prefer that physicians wear white coats; and more.

Coexisting bronchiectasis in patients with asthma and chronic rhinosinusitis is common and associated with more severe disease, according to new findings published in BMC Pulmonary Medicine.

Preservation of cardiorespiratory fitness over 2 decades was associated with lower odds for developing bronchiectasis on CT scans at 25 years, researchers reported in Radiology.

After 10 or more years of follow-up in the BT10+ study, bronchial thermoplasty for uncontrolled asthma demonstrated sustained efficacy and an acceptable safety profile, researchers reported in The Lancet Respiratory Medicine.

In the BATTLE trial, patients with non-cystic fibrosis bronchiectasis assigned tobramycin inhalation solution once daily had a nonsignificant decrease in number of exacerbations compared with placebo.

Adults with bronchiectasis and low levels of physical activity or high sedentary behaviors had an increased risk for hospitalization due to exacerbation at 1 year, according to a study published in the European Respiratory Journal.

Treatment with brensocatib for 24 weeks significantly prolonged time to first pulmonary exacerbation in patients with non-cystic fibrosis bronchiectasis compared with placebo, according to results from the WILLOW study.

The FDA has granted breakthrough therapy designation to brensocatib for the treatment of non-cystic fibrosis bronchiectasis in adults, according to a press release from Insmed.